1
|
Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 2005; 29:56-66. [PMID: 15598439 DOI: 10.1016/j.cyto.2004.09.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2004] [Accepted: 09/17/2004] [Indexed: 11/24/2022]
Abstract
We have determined the presence and kinetics of granulocyte macrophage colony stimulating factor (GM-CSF) antibodies induced after repeated administration of a yeast expressed GM-CSF product in prostate cancer patients with minimal recurrent disease using a panel of assays for detection and characterization of antibodies. Results showed that all 15 prostate cancer patients treated with GM-CSF developed GM-CSF reactive antibodies during the course of therapy. Most patients (87%) developed GM-CSF reactive antibodies within 3 months while in other patients (13%), these antibodies were induced after additional cycles of GM-CSF treatment. For most patients, the timing of occurrence of these antibodies was the same regardless of whether the ELISA or surface plasmon resonance (SPR) assays were used for detection. However, in two patients, the recognition of GM-CSF reactive antibodies by SPR assays preceded their detection by ELISA. A significant number of patients (n=9, 60%) developed GM-CSF antibodies which neutralized the biological activity of GM-CSF in vitro in a cell-line based bioassay. These antibodies also recognized GM-CSF protein from different expression systems including the non-glycosylated protein from E. coli indicating that the antibody response is directed towards the amino acid backbone of the protein. A significant effect of GM-CSF antibodies on PSA modulation was not observed in this small cohort of patients despite an alteration in PSA levels in some treated patients. The study design used here did not allow conclusions regarding the relationship between neutralizing antibodies and the PSA levels which were used as a marker for clinical outcome. Implementation of a clinical strategy which permits monitoring for antibody development and for levels of a relevant pre-determined clinical marker at appropriate time-points is necessary for assessing the impact of antibody development on the therapeutic efficacy of the protein.
Collapse
Affiliation(s)
- B Rini
- UCSF Comprehensive Cancer Center, Urologic Oncology Program University of California, San Francisco, CA 94115, USA
| | | | | | | | | | | |
Collapse
|
2
|
Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V, Bergman B, Egevad L, Hellström M, Kiessling R, Masucci G, Wersäll P, Nilsson S, Pisa P. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004; 91:688-94. [PMID: 15280930 PMCID: PMC2364780 DOI: 10.1038/sj.bjc.6602019] [Citation(s) in RCA: 143] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Prostate-specific antigen (PSA) is a serine protease secreted at low levels by normal luminal epithelial cells of the prostate and in significantly higher levels by prostate cancer cells. Therefore, PSA is a potential target for various immunotherapeutical approaches against prostate cancer. DNA vaccination has been investigated as immunotherapy for infectious diseases in patients and for specific treatment of cancer in certain animal models. In animal studies, we have demonstrated that vaccination with plasmid vector pVAX/PSA results in PSA-specific cellular response and protection against tumour challenge. The purpose of the trial was to evaluate the safety, feasibility and biological efficacy of pVAX/PSA vaccine in the clinic. A phase I trial of pVAX/PSA, together with cytokine granulocyte/macrophage-colony stimulating factor (GM-CSF) (Molgramostim) and IL-2 (Aldesleukin) as vaccine adjuvants, was carried out in patients with hormone-refractory prostate cancer. To evaluate the biologically active dose, the vaccine was administered during five cycles in doses of 100, 300 and 900 μg, with three patients in each cohort. Eight patients were evaluable. A PSA-specific cellular immune response, measured by IFN-γ production against recombinant PSA protein, and a rise in anti-PSA IgG were detected in two of three patients after vaccination in the highest dose cohort. A decrease in the slope of PSA was observed in the two patients exhibiting IFN-γ production to PSA. No adverse effects (WHO grade >2) were observed in any dose cohort. We demonstrate that DNA vaccination with a PSA-coding plasmid vector, given with GM-CSF and IL-2 to patients with prostate cancer, is safe and in doses of 900 μg the vaccine can induce cellular and humoral immune responses against PSA protein.
Collapse
Affiliation(s)
- M Pavlenko
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - A-K Roos
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - A Lundqvist
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - A Palmborg
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - A M Miller
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - V Ozenci
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - B Bergman
- Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden
| | - L Egevad
- Department of Pathology, 171 76 Karolinska University Hospital, Stockholm, Sweden
| | - M Hellström
- Department of Urology, Karolinska University Hospital, 171 76 Stockholm, Sweden
| | - R Kiessling
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
| | - G Masucci
- Department of Oncology, 171 76 Karolinska University Hospital, Stockholm, Sweden
| | - P Wersäll
- Department of Oncology, 171 76 Karolinska University Hospital, Stockholm, Sweden
| | - S Nilsson
- Department of Oncology, 171 76 Karolinska University Hospital, Stockholm, Sweden
| | - P Pisa
- Immune and Gene Therapy Laboratory, Cancer Center Karolinska, R8:01, Karolinska Institute, S-171 76 Stockholm, Sweden
- Department of Oncology, 171 76 Karolinska University Hospital, Stockholm, Sweden
- Cancer Center Karolinska, Immune and Gene Therapy, Karolinska Hospital S-171 76, Stockholm, Sweden. E-mail:
| |
Collapse
|